Search results
FDA approves MSD’s KEYTRUDA for advanced endometrial cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe US Food and Drug Administration (FDA) has approved MSD’s anti-PD-1 therapy KEYTRUDA for use with...
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
Morningstar· 5 days agoMerck said its blockbuster cancer drug Keytruda has been approved for the treatment of adult patients with primary advanced or recurrent ...
Gateway - Quartz
Quartz· 5 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an early-phase clinical trial testing the combined use of an experimental cancer
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
Clinical Trials Arena via Yahoo Finance· 4 days agoWhile AstraZeneca originally hoped for approval for all ...MSD) recently reported that its Phase III...
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Benzinga via Yahoo Finance· 5 days agoAstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 3 days agoModerna stock is making a turnaround after the Food and Drug Administration approved its second-ever...
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia,...
NBC New York· 5 days agoThe Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 2 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
FDA Expands Pembrolizumab Approval for Endometrial Cancer
Medscape· 5 days agoThe FDA expanded the approval of pembrolizumab based on improved PFS in patients with advanced or...
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street |...
The Motley Fool· 6 days agoSummit Therapeutics (SMMT -1.96%) is sizzling hot this year, with its shares skyrocketing around...